FDA Defends Ruzurgi Approval, Says It Did Not Flout Firdapse Exclusivity

By Beth Wang / September 5, 2019 at 11:51 AM

FDA denies allegations in an ongoing lawsuit with drug pricing undertones that two drugs approved to treat Lambert-Eaton myasthenic syndrome (LEMS), Firdapse and Ruzurgi, are the same even though they are indicated for different populations.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.